Viewing nowCombinationCrecantde 5/16 mg Tablet
Rosuvastatin Calcium 5.2mg · Candesartan Cilexetil 16mg
Tablet · Prescription medication · Combination
Korea Hutex Pharmaceutical Co., Ltd.

MFDS item code 202008722 · Approved 2020.12.11 · Insurance code 649105100
Treatment of hypertension and heart failure; improvement of dyslipidemia and atherosclerosis; suppression of cardiovascular disease risk
This medication is used for patients who require the simultaneous administration of two drugs: candesartan cilexetil and rosuvastatin. Candesartan cilexetil is used for the treatment of essential hypertension and for heart failure patients with impaired left ventricular function, as an adjuvant therapy to ACE inhibitors or when intolerable. Rosuvastatin is used as an adjunctive therapy when dietary therapy is not effective in patients with hypercholesterolemia and dyslipidemia, and it helps slow the progression of atherosclerosis. Additionally, it plays a role in reducing the risk of stroke, myocardial infarction, and vascular reintervention in patients at high risk of cardiovascular disease. Therefore, this medication is used to effectively improve hypertension and dyslipidemia and reduce the risk of cardiovascular disease.
This medicine is intended for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Use an initial dose of 4 mg, exercising particular caution in patients at high risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of 2 weeks or longer, up to a maximum of 32 mg once daily, taking the patient's tolerability into account. 2) Elderly patients, patients with intravascular volume depletion, renal impairment, or mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (typeIIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
○ Candesartan cilexetil, essential hypertension: Safety and efficacy have not been established in adolescents and children 18 years of age or younger. ○ Candesartan cilexetil, heart failure: Safety and efficacy have not been established in adolescents and children 18 years of age or younger.
This medication may cause serious harm to the fetus and newborn, especially during the second and third trimesters, and should be discontinued immediately if pregnancy is confirmed. This medication should not be administered to patients with certain liver diseases, severely impaired kidney function, muscle diseases, or hereditary angioedema. Additionally, women who may become pregnant must use adequate contraceptive measures before taking this medication, and those planning to become pregnant should consult their physician. Elderly patients, patients with weakened liver function, and those at risk of hyperkalemia should exercise caution while using this medication and should have regular blood tests and physical status evaluations. If symptoms such as muscle pain, muscle weakness, or muscle cramps occur, consult with a physician immediately, and necessary muscle-related tests should be performed to check for any abnormalities. This medication may also affect liver function, so liver enzyme levels should be monitored regularly before and during treatment, and if liver enzyme levels rise significantly, the medication should be discontinued. Interactions may occur when this medication is taken in combination with other drugs, so any current medications must be disclosed to medical personnel. In particular, if taken with potassium-sparing diuretics or medications that can cause hyperkalemia, blood potassium levels should be carefully monitored. This medication may cause transient dizziness or fatigue during driving or operating machinery, so caution is necessary. Keep out of reach of children, and do not transfer the medication to another container from its original packaging.
Headache, nasopharyngitis, localized infection, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, indigestion, elevated blood sugar, decreased serum sodium, hand fractures, hypoglycemia, nephrolithiasis, cough, headache, itching, nausea, dizziness, orthostatic dizziness, milia, periodontitis, inflammation, foreign body sensation, cataract, musculoskeletal pain, neck pain, elevated blood sugar, decreased serum sodium, hand fractures, hypoglycemia, nephrolithiasis, cough, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, constipation, nausea, abdominal pain, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorder, insomnia, nightmares, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, memory impairment, amnesia, dissociative disorder, cognitive dysfunction, confusion, severe muscle weakness, ophthalmoplegic weakness, dizziness, orthostatic dizziness, cerebral infarction, spondyloarthritis, musculoskeletal discomfort, pneumonia, femoral fracture, bruise, unstable angina, productive cough, idiopathic pulmonary fibrosis, worsening hypertension, unstable blood pressure, vertigo, adrenal insufficiency, acute renal failure, shock, syncope, loss of consciousness, hypotension, increased serum potassium, elevated creatinine, elevated ALT, elevated AST, elevated γ-GTP, liver dysfunction, jaundice, thrombocytopenia, agranulocytosis, hyperkalemia, hyponatremia, hypoglycemia, weakness, hunger, cold sweat, tremors, decreased concentration, convulsions, altered consciousness, intestinal vascular edema, diarrhea, interstitial pneumonia, fever, resolution, shortness of breath, abnormal chest X-ray, syncope, systemic pain, muscle cramps, gout, erectile dysfunction
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent air or moisture from entering, and it is recommended to keep it at a temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain the effectiveness and safety of the medication.
Pink round film-coated tablet
30 tablets/box [10 tablets/PTPX3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationRosuvastatin Calcium 5.2mg · Candesartan Cilexetil 16mg
Tablet · Prescription medication · Combination
Korea Hutex Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
AlboGen Korea Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Candesartan Cilexetil 32mg
Tablet · Prescription medication · Combination
Albogen Korea Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 16mg
Tablet · Prescription medication · Combination
Alvogen Korea Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
Alvogen Korea Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 16mg
Tablet · Prescription medication · Combination
Hanin Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
Hanin Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
Hanin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.